Swiss drug makers Lonza and Roche agreed in March ... S) completed its $1.2 billion purchase of Genentech’s Vacaville campus, considered home of the world’s largest biopharmaceutical ...

You can also read Eli Lilly chief scientist Daniel M. Skovronsky on fallacies surrounding patents, drug discovery, and affordability, Sandoz CEO Richard Saynor on what the 2024 conversation is ...

Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, reported on Monday that its experimental drug helped patients with a chronic ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 ...

a breast oncologist and clinical director for drug development at Memorial Sloan Kettering Cancer Center, said in a news release from drugmaker Genentech. Itovebi’s generic name is inavolisib ...

Genentech, a drug company, makes bevacizumab, ranibizumab, and faricimab. This company helps patients cover the cost of their products through the Genentech Patient Foundation. If you have ...

Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.

I’d like to think that Genentech and many other companies in our industry are starting to follow that approach. *This program requires pharmaceutical manufacturers in Medicaid to sell drugs at ...

Lonza (ticker LONN. S) completed its $1.2 billion purchase of Genentech’s Vacaville campus, considered home of the world’s largest biopharmaceutical manufacturing site, the Swiss drugmaker ...